EN106
EN106 is a potent inhibitor of FEMIB. EN106 is a cysteine-reactive covalent ligand. EN106 disrupts recognition of the key reductive stress substrate of FEM1B, FNIP1. EN106 reduces oxidative stress and rescues high glucose-induced impaired angiogenesis in HUVECs[1][2].
Product Specifications
CAS Number
[757192-67-9]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
E1/E2/E3 Enzyme; NF-κB; Reactive Oxygen Species (ROS) ; SOD
Type
Reference compound
Related Pathways
Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/en106.html
Purity
99.92
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
O=C(N(CCC#N)C1=CC=C(OCCO2)C2=C1)CCl
Molecular Formula
C13H13ClN2O3
Molecular Weight
280.71
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Parkin (FRA6E, Ubiquitin E3 Ligase PRKN, Parkinson Disease Protein 2, Parkinson Juvenile Disease Protein 2, PARK 2, PARK2, PDJ, Parkinson Disease (Autosomal Recessive Juvenile) 2, PRKN, LPRS 2, PRKN2, AR JP, PRKN 2, LPRS2, E3 Ubiquitin Protein Ligase Parkin) (HRP)
